Dr. Naoto Hirano’s research program aims to devise novel anti-tumor immunotherapeutic modalities that can cure cancer. Dr. Hirano’s research team is particularly interested in understanding how the interactions between T cells and antigen-presenting cells affect priming, expansion, persistence and differentiation of T cells, as well as how this leads to the subsequent generation and maintenance of anti-tumor T cell memory.
- Clinician Scientist I, OICR
- Assistant Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School
- Senior Investigator, OICR
- Associate Director for Research, Tumour Immunotherapy Program, Princess Margaret Cancer Centre
- Senior Scientist, Princess Margaret Cancer Centre
- Professor of Medicine, Department of Immunology, University of Toronto
- Sugata K, Matsunaga Y, Yamashita Y, Nakatsugawa M, …, Hirano N. Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+T cells. Nat Biotechnol. 2021.
- Murata K, Nakatsugawa M, Rahman MA, Nguyen LT, …, Hirano N. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma. eLife. 2020.
- Benveniste PM, Roy S, Nakatsugawa M, …, Hirano N, …, Zúñiga-Pflücker JC. Generation and molecular recognition of melanoma-associated antigen-specific human γδ T cells. Sci Immunol. 2018
- Kagoya Y, Tanaka S, Guo T, …, Hirano N. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018; 24(3):352-359.
- Yamashita Y, Anczurowski M, Nakatsugawa M, …, Hirano N. HLA-DP84Gly constitutively presents endogenous peptides generated by the class I antigen processing pathway. Nat Commun. 2017; 8:15244.
See Dr. Hirano’s recent publications on PubMed.
To collaborate with Dr. Hirano, please contact him directly.
Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.